Silver Book Fact

A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.

Mobley, Lee R., Thomas J. Hoerger, John S. Wittenborn, Debroah A. Galuska, and Jaya K. Rao. Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate. Medical Decision Making. 2006; 26(2): 194-206. http://mdm.sagepub.com/cgi/content/abstract/26/2/194

Reference

Title
Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate
Publication
Medical Decision Making
Publication Date
2006
Authors
Mobley, Lee R., Thomas J. Hoerger, John S. Wittenborn, Debroah A. Galuska, and Jaya K. Rao
Volume & Issue
Volume 26, Issue 2
Pages
194-206
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Genetics can account for up to 75% of bone mineral density (BMD). Researchers have identified a gene that strongly influences peak bone mass in mice. The gene was not previously…  
  • A meta-analysis of clinical trials found that calcium supplements reduced the risk of vertebral fractures by around 23%.  
  • Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by…  
  • A study that looked at a combination of calcium and Vitamin D found that hip fractures were reduced by around 43%.  
  • Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.